奥马珠

Search documents
石药集团(01093):2Q25仍承压但业绩拐点将至,研发、BD稳步推进,上调目标价
BOCOM International· 2025-08-25 11:41
交银国际研究 财务模型更新 | 医药 | 收盘价 | | 目标价 | | 潜在涨幅 | 2025 年 8 月 25 日 | | --- | --- | --- | --- | --- | --- | --- | | 港元 | | 10.51 | 港元 | 9.30↑ | -11.6% | | | 石药集团 (1093 HK) | | | | | | | 2Q25 仍承压但业绩拐点将至,研发、BD 稳步推进,上调目标价 公司的存量大单品在 2Q25 继续受到集采、院端医保控费等压力,但我们看好 2H25 及 2026-27 年业绩复苏的机会,考虑到上述影响即将出清、重磅 BD 首 付款对业绩的增厚、以及原料药/功能食品业务的反弹。我们上调目标价,当 前公司估值合理,正向催化剂预期和风险已基本反映在股价中,维持中性。 个股评级 中性 1 年股价表现 资料来源 : FactSet 8/24 12/24 4/25 8/25 -20% 0% 20% 40% 60% 80% 100% 120% 140% 1093 HK 恒生指数 股份资料 | 52周高位 (港元) | 10.96 | | --- | --- | | 52 ...
内地外贸生产景气6月后半月边际放缓
citic securities· 2025-07-02 09:28
Global Market Dynamics - The report indicates a mixed performance in the A-share market, with active trading in the chip and military sectors, while the Hong Kong market was closed for a holiday, and European markets experienced widespread declines due to trade negotiation concerns [3][9][11] - The U.S. labor market remains stable, with attention on Middle Eastern developments, while international oil prices showed mixed movements, and the dollar index slightly increased [4][27] Economic Indicators - High-frequency data suggests a marginal decline in industrial value-added growth in June, with export growth expected to remain stable compared to May. Infrastructure and manufacturing investments are anticipated to perform well, while real estate sentiment continues to decline [6] - The report highlights that the U.S. Senate passed Trump's tax reform and spending cut bill, and the Eurozone's inflation rate slightly increased to 2% in June [6] Stock Market Insights - The report notes that the U.S. stock market is experiencing a mixed performance, with the Dow Jones rising for four consecutive days, while large tech stocks faced declines. The S&P 500 and Nasdaq both retreated from record highs [9] - In the A-share market, the healthcare sector showed strong performance, while the blockchain concept stocks remained weak. The report emphasizes the rise of innovative drug stocks following supportive measures from health authorities [16][19] Sector Analysis - The report suggests a positive outlook for the U.S. tech sector in the next 6-12 months, driven by fiscal policies and easing trade tensions. Specific sub-sectors such as Robotaxi, Fintech, and AI ASIC are highlighted as areas of focus [8] - The Korean semiconductor and storage industry is noted for strong export performance in June, with expectations for continued robust average selling prices in the second half of 2025 [23] Company-Specific Developments - The report mentions that 和黄医药 (Hutchison China MediTech) is expected to enter a profitable phase with rapid overseas sales growth of its drug 呋喹替尼 (Fruquintinib) and stable domestic sales of 赛沃替尼 (Savolitinib) [14] - 新诺威 (Xinnoway) is highlighted for its promising clinical data on its EGFR ADC product, which shows significant potential for overseas licensing [19]